Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Consensus Price Target from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $12.40.

A number of research analysts have recently commented on the stock. HC Wainwright cut their price objective on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a research report on Monday, January 13th. Royal Bank of Canada dropped their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Oppenheimer decreased their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds have recently modified their holdings of INO. Deep Track Capital LP raised its position in Inovio Pharmaceuticals by 72.9% in the 4th quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company’s stock worth $5,708,000 after purchasing an additional 1,314,796 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in Inovio Pharmaceuticals in the fourth quarter worth about $1,922,000. AIGH Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $1,197,000. Bank of America Corp DE lifted its holdings in Inovio Pharmaceuticals by 1,035.2% in the fourth quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock valued at $1,173,000 after buying an additional 584,521 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Inovio Pharmaceuticals by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after acquiring an additional 6,874 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Stock Down 7.1 %

Shares of INO stock opened at $1.84 on Friday. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The firm has a market cap of $48.02 million, a PE ratio of -0.88 and a beta of 0.89. The stock has a 50 day moving average of $2.02 and a 200-day moving average of $4.24.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.